Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284883801> ?p ?o ?g. }
- W4284883801 endingPage "998" @default.
- W4284883801 startingPage "987" @default.
- W4284883801 abstract "Abstract The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head comparisons are lacking. To compare efficacy and safety of these regimens, we performed a network meta‐analysis of 27 phase 2/3 randomized trials including a total of 12,935 patients and 23 different schedules. Four efficacy/outcome and one safety indicators were extracted and integrated to obtain (for each treatment) the surface under the cumulative ranking‐curve (SUCRA), a metric used to build a ranking chart. With a mean SUCRA of 83.8 and 80.08 respectively, VMP + Daratumumab (DrVMP) and Rd + Daratumumab (DrRd) reached the top of the chart. However, SUCRA is designed to work for single outcomes. To overcome this limitation, we undertook a dimensionality reduction approach through a principal component analysis, that unbiasedly grouped the 23 regimens into three different subgroups. On the bases of our results, we demonstrated that first line treatment for NEMM should be based on DrRd (most active, but continuous treatment), DrVMP (quite “fixed‐time” treatment), or, alternatively, VRD and that, surprisingly, melphalan as well as Rd doublets still deserve a role in this setting." @default.
- W4284883801 created "2022-07-09" @default.
- W4284883801 creator A5001523948 @default.
- W4284883801 creator A5003679742 @default.
- W4284883801 creator A5016021915 @default.
- W4284883801 creator A5017141261 @default.
- W4284883801 creator A5018043620 @default.
- W4284883801 creator A5018769545 @default.
- W4284883801 creator A5019423518 @default.
- W4284883801 creator A5020123690 @default.
- W4284883801 creator A5021887337 @default.
- W4284883801 creator A5034393745 @default.
- W4284883801 creator A5046526239 @default.
- W4284883801 creator A5051626849 @default.
- W4284883801 creator A5057189669 @default.
- W4284883801 creator A5059065322 @default.
- W4284883801 creator A5078429053 @default.
- W4284883801 creator A5081396123 @default.
- W4284883801 creator A5083968415 @default.
- W4284883801 creator A5085841362 @default.
- W4284883801 date "2022-07-11" @default.
- W4284883801 modified "2023-10-18" @default.
- W4284883801 title "Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant" @default.
- W4284883801 cites W1556628912 @default.
- W4284883801 cites W1617328014 @default.
- W4284883801 cites W1943688743 @default.
- W4284883801 cites W1955748620 @default.
- W4284883801 cites W1988092780 @default.
- W4284883801 cites W1997326909 @default.
- W4284883801 cites W1999177459 @default.
- W4284883801 cites W2028399237 @default.
- W4284883801 cites W2074147400 @default.
- W4284883801 cites W2078752778 @default.
- W4284883801 cites W2082741854 @default.
- W4284883801 cites W2088095316 @default.
- W4284883801 cites W2091808438 @default.
- W4284883801 cites W2096207943 @default.
- W4284883801 cites W2101576302 @default.
- W4284883801 cites W2103289287 @default.
- W4284883801 cites W2104993929 @default.
- W4284883801 cites W2106530862 @default.
- W4284883801 cites W2110466835 @default.
- W4284883801 cites W2114217833 @default.
- W4284883801 cites W2120780398 @default.
- W4284883801 cites W2127192057 @default.
- W4284883801 cites W2143024657 @default.
- W4284883801 cites W2143860449 @default.
- W4284883801 cites W2158759120 @default.
- W4284883801 cites W2239467190 @default.
- W4284883801 cites W2280150890 @default.
- W4284883801 cites W2286059102 @default.
- W4284883801 cites W2319561761 @default.
- W4284883801 cites W2334764571 @default.
- W4284883801 cites W2344741804 @default.
- W4284883801 cites W2563021883 @default.
- W4284883801 cites W2563502964 @default.
- W4284883801 cites W2567188480 @default.
- W4284883801 cites W2591608295 @default.
- W4284883801 cites W2768741959 @default.
- W4284883801 cites W2769593282 @default.
- W4284883801 cites W2772566228 @default.
- W4284883801 cites W2908265631 @default.
- W4284883801 cites W2919022600 @default.
- W4284883801 cites W2947874495 @default.
- W4284883801 cites W2956888684 @default.
- W4284883801 cites W2966433679 @default.
- W4284883801 cites W2983448690 @default.
- W4284883801 cites W2990816134 @default.
- W4284883801 cites W2996752315 @default.
- W4284883801 cites W3007801283 @default.
- W4284883801 cites W3009874598 @default.
- W4284883801 cites W3019972849 @default.
- W4284883801 cites W3022981424 @default.
- W4284883801 cites W3032976214 @default.
- W4284883801 cites W3127986730 @default.
- W4284883801 cites W3136388199 @default.
- W4284883801 cites W3153066391 @default.
- W4284883801 cites W3159218044 @default.
- W4284883801 cites W3162625477 @default.
- W4284883801 cites W3174939712 @default.
- W4284883801 cites W3180549397 @default.
- W4284883801 cites W3202791180 @default.
- W4284883801 cites W3206192616 @default.
- W4284883801 cites W3206267283 @default.
- W4284883801 cites W4284883801 @default.
- W4284883801 doi "https://doi.org/10.1002/hon.3041" @default.
- W4284883801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35794705" @default.
- W4284883801 hasPublicationYear "2022" @default.
- W4284883801 type Work @default.
- W4284883801 citedByCount "3" @default.
- W4284883801 countsByYear W42848838012022 @default.
- W4284883801 countsByYear W42848838012023 @default.
- W4284883801 crossrefType "journal-article" @default.
- W4284883801 hasAuthorship W4284883801A5001523948 @default.
- W4284883801 hasAuthorship W4284883801A5003679742 @default.
- W4284883801 hasAuthorship W4284883801A5016021915 @default.
- W4284883801 hasAuthorship W4284883801A5017141261 @default.
- W4284883801 hasAuthorship W4284883801A5018043620 @default.